Trial Profile
An Open-Label Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Subjects With Thrombocytopenia Scheduled for a Surgical Procedure
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 30 Mar 2022
Price :
$35
*
At a glance
- Drugs Avatrombopag (Primary)
- Indications Thrombocytopenia
- Focus Registrational; Therapeutic Use
- Sponsors Swedish Orphan Biovitrum
- 05 Mar 2019 Status changed from recruiting to discontinued, as according to a Dova Pharmaceuticals media release, the company has decided to focus on developing DOPTELET for chronic immune thrombocytopenia (ITP) and chemotherapy-induced thrombocytopenia (CIT) and hence discontinued enrollment in the clinical trial evaluating the treatment of a broader population of patients with thrombocytopenia undergoing surgery (PST) and a post-marketing registry study for chronic liver disease (CLD) patients.
- 20 Dec 2017 Status changed from not yet recruiting to recruiting.
- 03 Nov 2017 New trial record